Squarepoint
SRPT icon

Squarepoint’s Sarepta Therapeutics SRPT Stock Holding History

Squarepoint’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$359K Sell
16,500
-39,000
-70% -$755K ﹤0.01% 3568
2025
Q4 		$1.19M Sell
55,500
-57,000
-51% -$1.2M ﹤0.01% 2458
2025
Q3 		$2.17M Buy
112,500
+84,700
+305% +$1.51M ﹤0.01% 2029
2025
Q2 		$475K Buy
27,800
+3,800
+16% +$162K ﹤0.01% 3321
2025
Q1 		$1.53M Sell
24,000
-12,400
-34% -$1.31M ﹤0.01% 2305
2024
Q4 		$4.43M Buy
36,400
+34,000
+1,417% +$4.17M ﹤0.01% 1741
2024
Q3 		$300K Buy
+2,400
New +$332K ﹤0.01% 3446

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's SRPT Position: Q1 2026 in Review

Squarepoint increased its Sarepta Therapeutics (SRPT) stake by 192% in Q1 2026, buying an estimated $1.89M and bringing the position to 148,802 shares worth $3.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

Squarepoint first reported a position in SRPT in Q4 2016 and has held it in 32 quarters since. The position peaked at $26.8M in Q4 2022. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Squarepoint held 148,802 shares of Sarepta Therapeutics worth $3.24M as of Q1 2026.
  • Squarepoint bought 97,866 Sarepta Therapeutics shares in Q1 2026, an estimated $1.89M.
  • Sarepta Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1827 holding.
  • Squarepoint first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 32 quarters since.
  • Squarepoint's Sarepta Therapeutics position peaked at $26.8M in Q4 2022.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.